Top Middle East pharmaceutical manufacturer forays into oncology market
Julphar has announced its entry into the oncology market through a license and supply agreement with Russia’s leading biotechnology company, BIOCAD.
Julphar will be partnering with BIOCAD and Health Authorities to register three leading specialized products to the UAE, which are used to treat breast cancer and other forms of cancers.
“We are delighted to be partnering with BIOCAD in the UAE market. Entering the oncology market is a huge step forward for Julphar,” commented Jerome Carle, General Manager, Julphar.
“Access to international markets is the number one priority of our company. That’s why we consider our cooperation with one of the largest pharmaceutical companies in the Middle East a turning point in our international business development,” observed Dmitry Morozov, CEO, BIOCAD.
